Lovisa Afzelius, Metaphore Biotechnologies CEO

Metaphore Biotech­nolo­gies seeks to mim­ic na­ture with $50M for au­toim­mune, im­munol­o­gy drugs out of Flag­ship

Flag­ship Pi­o­neer­ing has churned out an­oth­er biotech start­up that taps in­to na­ture’s seem­ing­ly end­less sup­ply of in­sights and, like many new life sci­ences com­pa­nies, is equip­ping its lab with ma­chine learn­ing to fine-tune its plat­form.

Af­ter years be­hind the scenes at the biotech in­cu­ba­tor, Metaphore Biotech­nolo­gies is out with an ini­tial $50 mil­lion from Flag­ship to mim­ic na­ture and go af­ter what­ev­er tar­gets it sees fit. The lofty goal match­es the vi­sion set forth by oth­er Flag­ship star­tups ini­tial­ly led by Metaphore CEO Lo­visa Afzelius; these in­clude Apri­ori Bio and All­tr­na.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.